While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...

We recently published an article titled, Jim Cramer is Talking About These 12 Stocks. In this article, we are going to take a ...

We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.